

1 INSIGHTS ENRICH YOUR DECISIONS WITH TAILOR-MADE EXTRACT AND ANALYSIS

1. PRICING OPTIMISATION

An original approach to setting and negotiating the right price through AI and predictive analytics.

3. MONITORING

A unified way to track the relevant timeframes you require to make your launch sequence bulletproof.

5. VALUE STORY

Write your market access roadmap, identify the conceptual frameworks in which you fit.

2. COMPETITIVE LANDSCAPE

Identify all the relevant comparators and their market access outcomes.


4. OUTCOMES DRIVERS

Discover what affects P&R outcomes and how to influence them.

6. LIKELIHOOD OF SUCCESS

Assess the probability of success of the scenario you have developed at each steps of the P&R procedure.





YOUR BENEFITS

- ✓ We help you **save time**
- ✓ Your strategy is based on **reliable and systematic evidence**
- ✓ **Auditable data** with a regulatory link to the source for each data
 - ✓ NETIS.AI's databases and analyses are ready to use

OUR METHODOLOGY

- ✓ Creation of **custom search algorithms**
- ✓ Application to our in-house AI-powered database
- ✓ **Control, analysis, and interpretation** of data by life science experts
 - ✓ Presentation and delivery of the data files

#1 CASE STUDY: PRICING OPTIMISATION



“Informing a new medicine launch”

01

Challenge

Collecting price and HTA history of all listed/delisted products in a new indication yet unknown to a top-tier pharmaceutical company.

02



03

Results

- ✓ 5 800 price points over 20 years ;
- ✓ Average price erosion %/year ;
- ✓ Class renegotiations identification, outcomes and frequency ;
- ✓ Characterisation of overperforming prices vs comparators and HTA results.

*25 - 35 days of work saved compared to manual data aggregation and analysis

#2 CASE STUDY: **OUTCOME DRIVERS**


“Deepening a CT reassessment strategy”

01

Challenge

Anticipating time frames, price cuts and HTA outcomes after a signal from the HAS.

02



Medicine	Year	Price	Outcome
Medicine A	2018	100	Approved
Medicine A	2019	95	Approved
Medicine A	2020	90	Approved
Medicine B	2018	120	Approved
Medicine B	2019	115	Approved
Medicine B	2020	110	Approved

03

Results

- ✓ 1556 pertinent data points over 44 years;
- ✓ Reassessments outcomes history regarding 14 medicines;
- ✓ Characterisation of clinical endpoints discussed by the CT;
- ✓ Average price erosion post-reassessment.

*12 - 15 days of work saved compared to manual data aggregation and analysis.

#3 CASE STUDY - MONITORING


“Outsourcing HTA and P&R monitoring”

01

Challenge

Automating the HTA and P&R monitoring to reduce data collection time and increase data analysis time.

02



©NETIS AI - all rights reserved

03

Results

- ✓ 1 200 - 1 800 data points;
- ✓ HTA history on >40 medicines;
- ✓ Charts and graphics to quickly have an overview of critical pertinent metrics.
- ✓ Periodic updates every few months of the file.

*3-4 days a month saved compared to manual data aggregation and analysis.

#4 CASE STUDY – LIKELYHOOD OF SUCCESS

“Market access trajectory”

01

Challenge

Accessing the market access potential of early assets.

02



03

Results

- ✓ > 1 500 pertinent data points between each regulatory steps
- ✓ Average likelihood of success and timelines to pass each step of the P&R procedure in France;
- ✓ Charts and graphics to quickly understand over-performing products.